Understanding profiles of patients with treatment-resistant depression by stringency of health plan prior authorization criteria for approval of esketamine nasal spray-Reference-Cited by-同舟云学术

Understanding profiles of patients with treatment-resistant depression by stringency of health plan prior authorization criteria for approval of esketamine nasal spray

Published:2024-07-24 Issue:9 Volume:40 Page:1615-1623
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Harding Lisa¹,Zhdanava Maryia²,Shah Aditi²,Pesa Jacqueline³,Totev Todor I.⁴,Tardif-Samson Anabelle²,Pilon Dominic²,Joshi Kruti³

Affiliation:

1. Mood Institute, Milford, CT, USA

2. Analysis Group, Inc, Montréal, QC, Canada

3. Janssen Scientific Affairs, LLC, a Johnson & Johnson Company, Titusville, NJ, USA

4. Analysis Group, Inc, Boston, MA, USA

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2024.2380743

Reference32 articles.

1. U.S. Food and Drug Administration. FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic; 2021 [cited June 7]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified.

2. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Major depressive disorder: developing drugs for treatment guidance for industry; Jun 2018 [cited 2024 Jan 10]. Available from: https://www.fda.gov/media/113988/download.

3. A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials

4. The identification, assessment and management of difficult-to-treat depression: An international consensus statement

5. Safety and effectiveness of intranasal esketamine for treatment-resistant depression: a real-world retrospective study